M
easles virus (MV) is an enveloped virus that belongs to the genus Morbillivirus of the family Paramyxoviridae and possesses two types of surface glycoprotein spikes, the hemagglutinin (H) and fusion (F) proteins. MV infection is initiated by binding of the H protein to cellular receptors on the target host cells. The binding triggers membrane fusion between the virus envelope and the host cell plasma membrane mediated by the F protein. The signaling lymphocyte activation molecule (SLAM) on a subset of immune cells and nectin4 at adherens junctions are the principal receptors for MV (1) (2) (3) (4) . The H and F proteins are both neutralizing targets, but greater amounts of antibodies (Abs) are elicited against the H protein than the F protein, and the H protein-specific antibodies mainly contribute to neutralization of MV infection in vivo (5) (6) (7) (8) . All the available data suggest that measles eradication is biologically feasible (9, 10) , and one of the major factors that would ensure measles eradication is the single-serotype nature of MV. Our previous paper suggested that the receptor-binding site (RBS) on the H protein, which is exposed outside the heavy N-glycan shields, may constitute a major neutralizing epitope that contributes to the single-serotype nature of MV (11) . However, our recent paper (12) showing the detailed locations of five epitopes (I, II, iv, v, and vi) on the H protein provided insufficient evidence that the RBS acts as a neutralizing epitope. Here, we provide direct and concrete evidence that the RBS itself forms an effective conserved neutralizing epitope (CNE) which provides a strong functional constraint against change.
In the present study, we characterized a new mouse monoclonal antibody (MAb), 2F4. MAb 2F4 was produced using a cell line expressing the H protein of the wild-type IC-B strain as an antigen. For competitive binding enzyme-linked immunosorbent assays (cELISAs), MV antigens precoated on cELISA plates (Denka Seiken) were incubated with previously reported MAbs (E81, E128, E185, E39, and E103) (12, 13) , 2F4, or phosphate-buffered saline for 1 h and then incubated with MAb 2F4 labeled with biotin using a biotin labeling kit (NH2; Dojindo Laboratories). After three washes, the MV antigens bound by the MAbs were incubated with a streptavidin-horseradish peroxidase (HRP) conjugate (Thermo Scientific) for 1 h before addition of the TMB substrate (3,3=5,5=-tetramethylbenzidine; Denka Seiken). The plates were incubated for 25 min, and the colorimetric reactions were stopped by addition of H 2 SO 4 . The optical density (OD) values were analyzed using a microplate reader (Bio-Rad). The data revealed that binding of 2F4 was not inhibited by MAbs recognizing epitopes I, iv, v, and vi (E81, E185, E39, and E103, respectively) (12) ( Table 1 ; the epitope recognized by 2F4 is tentatively termed epitope vii). On the other hand, E128 recognizing epitope II (12) showed partial inhibition of 2F4 binding (Table 1) . Epitope II is shielded by the N-glycan modification at amino acid position 416 (N416-sugar), and viruses with the N416-sugar (genotypes D3, D4, D5, and D9 among the eight genotypes) are not neutralized by E128 (12) . Eight distinct recombinant MVs (rMVs) encoding a Renilla luciferase reporter gene and an H gene derived from different MV genotypes (A, B3, D3, D4, D5, D8, D9, and H1) were used as neutralization targets for 2F4 (Table 2) , as reported previously (12) . The data clearly demonstrated that, unlike E128 recognizing epitope II, 2F4 showed high neutralizing titers against all eight rMVs (Table 2 ). These data suggested that epitope vii is a CNE and is distinct from all the other five epitopes (I, II, iv, v, and vi).
When the H protein-SLAM interaction was assessed by surface plasmon resonance assays, as reported previously (12), MAb 2F4 blocked binding of the H protein to SLAM, as did MAbs B5 and E128 recognizing epitopes I and II, which are located near the RBS (12) ( Table 3 ). These data suggest that epitope vii is located at or near the RBS. A panel of rMVs possessing amino acid substitutions at the RBS were analyzed for neutralization by 2F4. On the D3 genetic background (IC323 strain [14] ), four rMVs encoding enhanced green fluorescent protein (EGFP) and possessing mutations at a SLAM-interacting residue (R533A) (Fig. 1B) and nectin4-interacting residues (F483A, Y543S, and S544A/Y541S) ( Fig. 1C ) (15) (16) (17) (18) (19) were generated and assessed for virus spreading in SLAM-positive (SLAM ϩ ) B95a and nectin4 ϩ II-18 cells (20) in the presence or absence of 2F4 (Fig. 2) . The rMVs with F483A and Y543S were reported previously (15) . As shown in Fig. 2 , in the absence of 2F4 [Ab(Ϫ)], wild-type MV spread efficiently in both cell types using SLAM or nectin4. On the other hand, rMVs with F483A, Y543S, or S544A/Y541S lost the ability to use nectin4 as a receptor and thus failed to spread in II-18 cells, even in the absence of 2F4. Similarly, rMV with R533A lost the ability to use SLAM as a receptor and did not spread in B95a cells. However, in the presence of 2F4, the mutant MVs showed advantages for spreading. Even in the presence of 2F4, rMVs with F483A, Y543S, or S544A/ Y541S were able to spread in SLAM ϩ B95a cells, and rMV with R533 was able to spread in nectin4 ϩ II-18 cells, whereas the wildtype MV infection was completely neutralized by 2F4. Similar experiments were performed using luciferase-expressing rMVs (21) . Two rMVs with mutations at SLAM-interacting residues (D505S and R533A) (17, 19) (Fig. 1B) and two rMVs with mutations at nectin4-interacting residues (F483A and Y543S) (15, 16, 18) (Fig.  1C) were generated (rMVs with F483A and Y543S were reported previously [15] ). In part, as reported previously, rMVs with F483A (15) and Y543S (15) were unable to bind to nectin4 (2, 3), and those with R533A (16) and D505S (in the present study) lost the ability to use SLAM (Table 4) . Meanwhile, the F483A, Y543S, D505S, and R533A substitutions all resulted in escape from neutralization by 2F4 (Table 4 ). These data demonstrated that the RBS used for interactions with both SLAM and nectin4 constitutes epitope vii recognized by 2F4 (Fig. 1) . Consequently, MV escape 
vii ϩϩ a ϩϩ, complete inhibition; ϩ, partial inhibition; Ϫ, no inhibition. 
The detailed procedure has been previously reported (12) . b ϩϩ, complete inhibition; Ϫ, no inhibition.
FIG 1 Location of epitope vii on the H protein tetrameric structure. (A)
Diagram of an H protein tetramer (a dimer of H protein dimers). The four H protein molecules are shown in dark gray, light gray, dark purple, and light purple. (B) Location of SLAM-interacting residues, which constitute epitope vii on the tetrameric H protein structure in complex with SLAM (19) . SLAM is shown in translucent cyan. SLAM interacting with the gray H protein is deleted in the structure shown at the bottom. A detailed view in a ribbon and stick diagram is shown in the box. SLAM is shown in cyan, and H protein is shown in orange or yellow. (C) Location of nectin4-interacting residues, which constitute epitope vii. The tetrameric structure was reconstructed using data by Hashiguchi et al. (19) and Zhang et al. (18) . Nectin4 is shown in translucent magenta. Nectin4 interacting with the gray H protein is deleted in the structure shown at the bottom. A detailed view in a ribbon and stick diagram is shown in the box. Nectin4 is shown in magenta, and H protein is shown in orange or yellow. (B and C) The figures were produced using PyMOL (Schrödinger; http://www.pymol.org). The amino acid residues demonstrated or suggested to constitute portions of epitopes are shown in colors as follows: residues on beta-sheets 1, 2, 3, 4, 5, and 6 (19) are shown in blue, dark green, light green, yellow, orange, and red, respectively.
from neutralization by 2F4 is penalized by loss of affinity for one of the principal MV receptors. Apparently, a previously reported MAb, I-41, also recognizes this vii epitope (22) , since a substitution at position 552 (the phenylalanine at this position is predicted to interact with SLAM [19] ) allowed MV to escape from neutralization. Another previous study implied that MAb 80-II-B2 recognizes a region containing residues 505 and 506 within this epitope (23) . The H protein of the CAM-70 MV vaccine strain features a mutation at position 505. Accordingly, the CAM-70 vaccine strain does not react with 80-II-B2 and binds to SLAM inefficiently (23, 24) . Previous competitive binding studies revealed that MAb 16-DE6 recognizes the same antigenic site as I-41 (25) , and that an 16-DE6 escape mutant contained, among other changes, an arginine-to-glycine substitution at position 533 (R533G) (22) . Previously characterized MAbs B2 and BH26 similarly recognize this epitope (6, 25, 26) , which appears to be a premier neutralizing epitope for the H protein.
Residues located in this epitope may be involved in SLAM-binding activity (6, 26) . Therefore, this region probably corresponds to epitope vii identified in our study.
In summary, the present data demonstrate that both the SLAM-and nectin4-interacting residues themselves constitute a CNE. Since these residues are critical for interaction with either SLAM or nectin4, viral escape from neutralization has to be associated with loss of the receptor-binding activity. Since efficient MV spreading mandates interactions of the H protein with these two discrete proteinaceous receptors, SLAM and nectin4 (4), residues within this domain are likely to be under high selective pressure to maintain their molecular identity, and contribute to the sustainability of the single-serotype nature of MV. 
